Display options
Cite
Castellino A, Santambrogio E, Nicolosi M, et al. Follicular Lymphoma: The Management of Elderly Patient. Mediterr J Hematol Infect Dis. 2017;9(1):e2017009doi: 10.4084/MJHID.2017.009.
Castellino, A., Santambrogio, E., Nicolosi, M., Botto, B., Boccomini, C., & Vitolo, U. (2017). Follicular Lymphoma: The Management of Elderly Patient. Mediterranean journal of hematology and infectious diseases, 9(1), e2017009. https://doi.org/10.4084/MJHID.2017.009
Castellino, Alessia, et al. "Follicular Lymphoma: The Management of Elderly Patient." Mediterranean journal of hematology and infectious diseases vol. 9,1 (2017): e2017009. doi: https://doi.org/10.4084/MJHID.2017.009
Castellino A, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U. Follicular Lymphoma: The Management of Elderly Patient. Mediterr J Hematol Infect Dis. 2017 Jan 01;9(1):e2017009. doi: 10.4084/MJHID.2017.009. eCollection 2017. PMID: 28105297; PMCID: PMC5224805.
Copy Download .nbib Format: NLM
Share it on

Mediterr J Hematol Infect Dis. 2017 Jan 01;9(1):e2017009. doi: 10.4084/MJHID.2017.009. eCollection 2017.

Follicular Lymphoma: The Management of Elderly Patient.

Mediterranean journal of hematology and infectious diseases

Alessia Castellino, Elisa Santambrogio, Maura Nicolosi, Barbara Botto, Carola Boccomini, Umberto Vitolo

Affiliations

  1. Città della Salute e della Scienza University and Hospital, Hematology Unit, Turin, Italy.

PMID: 28105297 PMCID: PMC5224805 DOI: 10.4084/MJHID.2017.009

Abstract

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, which typically affects mature adults and elderly, whose median age at diagnosis is 65 years. The natural history of FL appears to have been favorably impacted by the introduction of Rituximab. Randomized clinical trials demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival and new strategies of chemo-immunotherapy, such as Bendamustine combined with Rituximab, showed optimal results on response and reduced hematological toxicity, becoming one of the standard treatments, particularly in elderly patients. Moreover, maintenance therapy with Rituximab demonstrated improvement of progression-free survival. Despite these exciting results, FL is still an incurable disease. It remains a critical unmet clinical need finding new prognostic factors to identify poor outcome patients better, to reduce the risk of transformation and to explore new treatment strategies, especially for patients not candidate to intensive chemotherapy regimens, such as elderly patients. Some progress were already reached with novel agents, but larger and more validated studies are needed. Elderly patients are the largest portion of patients with FL and represent a subgroup with higher treatment difficulties, because of comorbidities and smaller spectrum for treatment choice. Further studies, focused on elderly follicular lymphoma patients, with their peculiar characteristics, are needed to define the best-tailored treatment at diagnosis and at the time of relapse in this setting.

Keywords: Comorbidities; Elderly; Follicular Lymphoma

References

  1. Blood. 2000 Feb 1;95(3):783-9 - PubMed
  2. Br J Haematol. 2014 Mar;164(5):710-6 - PubMed
  3. Blood. 2005 Sep 15;106(6):2169-74 - PubMed
  4. Blood. 2014 May 8;123(19):2944-52 - PubMed
  5. Radiol Clin North Am. 2008 Mar;46(2):213-23, vii - PubMed
  6. Blood. 2016 May 19;127(20):2375-90 - PubMed
  7. Blood. 2016 Apr 28;127(17):2055-63 - PubMed
  8. J Clin Oncol. 2012 Nov 1;30(31):3848-53 - PubMed
  9. J Clin Oncol. 2004 Apr 15;22(8):1454-9 - PubMed
  10. N Engl J Med. 2014 Mar 13;370(11):1008-18 - PubMed
  11. J Clin Oncol. 2014 Sep 20;32(27):3059-68 - PubMed
  12. J Clin Oncol. 1998 Apr;16(4):1582-7 - PubMed
  13. J Clin Oncol. 2010 Jun 10;28(17):2853-8 - PubMed
  14. Blood. 2013 Nov 28;122(23):3759-66 - PubMed
  15. Cancer. 2010 Aug 15;116(16):3843-51 - PubMed
  16. Blood. 2004 Sep 1;104(5):1258-65 - PubMed
  17. Lancet Oncol. 2014 Apr;15(4):457-63 - PubMed
  18. Clin Cancer Res. 2007 Oct 1;13(19):5784-9 - PubMed
  19. Blood. 1994 Sep 1;84(5):1361-92 - PubMed
  20. JAMA. 1963 Sep 21;185:914-9 - PubMed
  21. J Clin Exp Hematop. 2016;56(1):1-19 - PubMed
  22. J Clin Oncol. 2013 Sep 20;31(27):3307-8 - PubMed
  23. Blood. 2006 Dec 15;108(13):4003-8 - PubMed
  24. J Clin Oncol. 2013 Jun 1;31(16):1977-83 - PubMed
  25. J Clin Oncol. 2005 Nov 20;23(33):8447-52 - PubMed
  26. J Am Geriatr Soc. 1993 Nov;41(11):1245-54 - PubMed
  27. J Clin Oncol. 2013 Apr 20;31(12):1506-13 - PubMed
  28. Crit Rev Oncol Hematol. 2003 May;46(2):127-37 - PubMed
  29. Cancer. 2009 Oct 1;115(19):4547-53 - PubMed
  30. Blood. 2005 Dec 1;106(12):3725-32 - PubMed
  31. J Clin Oncol. 2009 Sep 20;27(27):4555-62 - PubMed
  32. J Psychiatr Res. 1975 Nov;12(3):189-98 - PubMed
  33. Exp Hematol Oncol. 2015 Jun 24;4:17 - PubMed
  34. J Clin Oncol. 1997 Mar;15(3):1110-7 - PubMed
  35. J Clin Oncol. 1996 Apr;14(4):1282-90 - PubMed
  36. Br J Cancer. 2011 Nov 22;105(11):1684-92 - PubMed
  37. Gerontologist. 1969 Autumn;9(3):179-86 - PubMed
  38. Haematologica. 2007 Jun;92(6):826-33 - PubMed
  39. Cancer Control. 2003 Nov-Dec;10(6):463-8 - PubMed
  40. Haematologica. 2013 Jul;98(7):1107-14 - PubMed
  41. Leuk Lymphoma. 2015 Apr;56(4):921-6 - PubMed
  42. Lancet Oncol. 2015 Sep;16(9):1111-22 - PubMed
  43. Br J Haematol. 2013 Nov;163(4):465-77 - PubMed
  44. Semin Oncol. 2000 Dec;27(6 Suppl 12):37-41 - PubMed
  45. Blood. 2006 Nov 15;108(10):3295-301 - PubMed
  46. Adv Immunol. 2011;111:1-46 - PubMed
  47. Lancet. 2013 Apr 6;381(9873):1203-10 - PubMed
  48. Lancet Oncol. 2016 Aug;17(8):1081-93 - PubMed
  49. J Clin Oncol. 2015 Nov 1;33(31):3635-40 - PubMed
  50. Lancet Oncol. 2014 Nov;15(12):1311-8 - PubMed
  51. J Clin Oncol. 2013 Sep 20;31(27):3351-9 - PubMed
  52. J Clin Oncol. 1999 Aug;17(8):2499-505 - PubMed
  53. J Clin Oncol. 1988 Dec;6(12):1838-44 - PubMed
  54. Leuk Lymphoma. 1993 Jun;10(3):147-56 - PubMed

Publication Types